Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-10

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

3mg Liraglutide for Overweight or Obesity

NCT03885297

Overweight Obesity Infertility, Female

COMPLETED

The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients

NCT04605861

Obese Overweight

COMPLETED PHASE3

Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg

NCT03534310

Obesity

COMPLETED NA

Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities

NCT04487743

Obesity

UNKNOWN PHASE3

Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

NCT02718950

Obesity Type 2 Diabetes Mellitus

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Morbid Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liraglutide

drug starts 6 weeks post-operative until 6 months SC injection dose starting 0.6 mg/day and weekly up titrated until 3.0 mg/day

Group Type EXPERIMENTAL

Liraglutide Pen Injector [Saxenda]

Intervention Type DRUG

Subcutaneous injection of GLP-1 agonist

Control

Patients with no weight loss drug intervention after bariatric surgery

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liraglutide Pen Injector [Saxenda]

Subcutaneous injection of GLP-1 agonist

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Undergone primary bariatric surgery
* Need secondary bariatric surgery due to either weight regain (regained weight to have BMI \> 35) or medical associated diseases

Exclusion Criteria

* Prior use of GLP-1 agonist
* Past history of pancreatitis
* Personal or family history of medullary thyroid cancer
* Pregnancy or lactation
* Acute coronary syndrome
* Hepatic or renal dysfunction
* Active malignancy

Eligible Sex

ALL

Accepts Healthy Volunteers

No